Immunotherapy before surgery for certain colorectal cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage II or III colorectal cancer (spread to nearby tissue but not distant organs)
- Your tumor has a specific DNA repair problem (called dMMR or MSI-High), confirmed by testing
- You are healthy enough for surgery (no other serious health problems that would make surgery risky)
- You do not have an active autoimmune disease, active infection, or inflammatory bowel disease
- You are not allergic to tislelizumab or similar immunotherapy drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests whether giving immunotherapy before surgery, with or without radiation, can help shrink locally advanced colorectal cancer that has a specific genetic marker (MSI-H or dMMR). It aims to improve outcomes for patients who have not yet had any treatment.
This Phase 2 trial studies whether adding tislelizumab to standard chemo (CAPOX) around the time of surgery can lower the risk of colon or rectal cancer coming back. It’s for people with stage II or III tumors that have an MSI-H or dMMR test result, which may mean they’re more likely to respond to immune-based treatment.
This trial tests tislelizumab given after colon cancer surgery to lower the risk of the cancer coming back. It is for people with stage II or III colon cancer that has defective mismatch repair (dMMR).
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
Hear when a new Colo-rectal Cancer (dMMR/MSI-H CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.